BRAF wild-type

Of note, 6/7 cases with HER-2 mutations exhibited limited benefit from treatment with FOLFIRI plus cetuximab with PFS inferior to 8 months. Taken together, these results highlight the need to test HER-2 gene alterations for patients with RAS/BRAF V600 WT, MSS mCRC, who are candidates for anti-epidermal growth factor receptor therapies.

P=N/A, N=250, Recruiting, Niguarda Hospital

The patient was thereafter treated with a combination of pembrolizumab, nab-paclitaxel and carboplatin, resulting in a sustained near-complete response lasting over 30 months, accompanied by a manageable safety profile. The favorable response in this case suggests that further evaluation of this triplet regimen could be considered for anaplastic thyroid cancer, though this remains a speculative premise requiring validation. Further studies are also needed to clarify the underlying mechanisms of this combination and to identify predictive biomarkers for patient selection.

Patients were randomized (1:1) to FOLFIRI-cetuximab then mFOLFOX6-bevacizumab (arm A) or OPTIMOX-bevacizumab then FOLFIRI-bevacizumab followed by EGFR monoclonal antibody +/- irinotecan (arm B)...Adverse events were consistent with the well-known safety profiles. STRATEGIC-1 did not meet its primary endpoint and was inconclusive in identifying the optimal treatment strategy in wild-type RAS/BRAFV600E mCRC.

P1, N=9, Recruiting, West China Hospital | Not yet recruiting --> Recruiting

The patient was rechallenged with standard-dose IPINIVO (3: 1 mg/kg iplimumab: nivolumab) and achieved excellent clinical response despite multiple treatment-delaying toxicities: grade 2 cytokine release syndrome after cycle 1 and grade 2 pneumonitis and grade 3 colitis after cycle 2, managed with high-dose prednisone. CONCLUSIONS There are limited data on the benefit and safety of IPINIVO with rechallenge in patients who achieved initial PFS longer than 2 years, warranting further research in populations with resistant disease. Long-term safety data from rechallenge responders are needed.

P=N/A, N=140, Completed, AstraZeneca | Recruiting --> Completed | N=105 --> 140

P1, N=9, Not yet recruiting, West China Hospital

Interestingly, some of these patients may derive meaningful benefit from cytotoxic chemotherapy. We present the report of a case of a 63-year-old lady with BRAF wild type, locally advanced mucosal melanoma who demonstrated disease progression on combination immunotherapy with Ipilimumab and nivolumab. She subsequently achieved an exceptional and durable radiological and clinical response to chemotherapy with cisplatin and dacarbazine. This case highlights that, despite advances in personalized medicine and immunotherapy, conventional chemotherapy may still represent a valuable therapeutic option in selected patients, particularly in the refractory setting.

This study demonstrates significant alterations in the miRNA expression profile in metastatic melanoma and highlights the potential of miR-146a-5p and miR-4286 as key regulators of tumor biology.

Trastuzumab-based combinations and HER2-selective tyrosine kinase inhibitors such as tucatinib have demonstrated durable responses and favorable safety profiles in heavily pretreated patients. This review summarizes current evidence from pivotal phase II and III clinical trials, translational studies, and real-world data evaluating EGFR-, BRAF-, and HER2-directed therapies in colorectal cancer. Particular emphasis is placed on biomarker-guided patient selection, mechanisms of resistance, and emerging combination strategies that continue to refine precision oncology approaches in mCRC.

P1/2, N=117, Recruiting, Georgiamune Inc | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Dec 2025 --> Dec 2026